Fig. 3
Heterodimeric EGFR and HER2 T-BsAbs impede PDAC growth (A) In vivo antitumor effect of BsAbs in the presence of human T cells against SW1990 cell line xenografts; 3 × 106 cells of SW1990 were subcutaneously implanted into mice. T-BsAbs were administered twice per week and 2 × 107 of luciferase-transduced T cells (Luc(+) T cells) were administered once per week for 2 weeks to treat the tumors. (B) In vivo anti-tumor effects of 10 µg EGFR and HER2 T-BsAbs. (C) Relative body weight of mice during treatment and (D) overall survival were plotted. (E) Bioluminescence imaging (BLI) of Luc(+) T cells. Quantitation of bioluminescence intensity in the lesions of tumors. Representative images (right) were taken on day 7